Retina Institute of California Advances Stem Cell Research

Arcadia, CA (PRWEB) September 25, 2013

Retina Institute (RIC) announced that its ground-breaking study, using stem-cell based therapy for advanced geographic atrophy, won FDA approval to move into the next phase.

"Our original work with 29 patients in the Phase 1b/2a showed a positive result in a large enough group of patients to warrant advancement of this study, said Michael Samuel, MD, Retina Institute surgeon and co-founder. There are only two sites in the world that are providing this treatment for advanced macular degeneration (AMD), and that is here at RIC and in Philadelphia.

The study will allow patients with 20/80 or worse vision with central geographic atrophy related to AMD. The cells in use are non-embryonic in nature, are registered with the National Institute of Health Clinical Trials registry, and will be zero out-of-pocket cost for patients. There will also be modest compensation for visit-related expenses.

This research was recently highlighted at the annual meeting of American Society of Retina Specialists where four RIC surgeons were asked to present.

A point I would like to make with significant pride is that at present, our surgeons have the largest experience of delivering stem cells to patients for AMD in the world," added Samuel.

For further information about this study or to refer a patient to RIC, please contact RIC at 800-898-2020. Space is limited.

About Retina Institute The Retina Institute was founded on a model of exceptional patient care and clinical excellence and is recognized as one of the nations leading practices specializing in vitreoretinal diseases. With 15 highly-trained retina surgeons in 24 centers, Retina Institute is committed to innovation, compassion and superior results, and works in close partnership with each other and with referring doctors to achieve the best possible outcome for every patient. For more information, visit retina2020.com.

Read the original post:
Retina Institute of California Advances Stem Cell Research